These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 18498916)

  • 81. Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation.
    van Hest R; Mathot R; Vulto A; Weimar W; van Gelder T
    Ther Drug Monit; 2005 Apr; 27(2):163-7. PubMed ID: 15795646
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine.
    Pan H; Gazarian A; Fourier A; Gagnieu MC; Leveneur O; Sobh M; Michallet MC; Buff S; Roger T; Dubernard JM; Michallet M
    Transplant Proc; 2014 Dec; 46(10):3620-8. PubMed ID: 25498100
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
    de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
    Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 86. No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.
    Rissling O; Glander P; Hambach P; Mai M; Brakemeier S; Klonower D; Halleck F; Singer E; Schrezenmeier EV; Dürr M; Neumayer HH; Budde K
    Br J Clin Pharmacol; 2015 Nov; 80(5):1086-96. PubMed ID: 25913040
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Associations of UDP-glucuronosyltransferases polymorphisms with mycophenolate mofetil pharmacokinetics in Chinese renal transplant patients.
    Xie XC; Li J; Wang HY; Li HL; Liu J; Fu Q; Huang JW; Zhu C; Zhong GP; Wang XD; Sun PP; Huang M; Wang CX; Li JL
    Acta Pharmacol Sin; 2015 May; 36(5):644-50. PubMed ID: 25864649
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients.
    Cattaneo D; Gaspari F; Ferrari S; Stucchi N; Del Priore L; Perico N; Gotti E; Remuzzi G
    Clin Transplant; 2001 Dec; 15(6):402-9. PubMed ID: 11737117
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study.
    Noreikaitė A; Saint-Marcoux F; Marquet P; Kaduševičius E; Stankevičius E
    Medicine (Baltimore); 2017 Mar; 96(13):e6469. PubMed ID: 28353583
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.
    Le Meur Y; Büchler M; Thierry A; Caillard S; Villemain F; Lavaud S; Etienne I; Westeel PF; Hurault de Ligny B; Rostaing L; Thervet E; Szelag JC; Rérolle JP; Rousseau A; Touchard G; Marquet P
    Am J Transplant; 2007 Nov; 7(11):2496-503. PubMed ID: 17908276
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity.
    Borrows R; Chusney G; Loucaidou M; James A; Lee J; Tromp JV; Owen J; Cairns T; Griffith M; Hakim N; McLean A; Palmer A; Papalois V; Taube D
    Am J Transplant; 2006 Jan; 6(1):121-8. PubMed ID: 16433766
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.
    Sommerer C; Müller-Krebs S; Schaier M; Glander P; Budde K; Schwenger V; Mikus G; Zeier M
    Br J Clin Pharmacol; 2010 Apr; 69(4):346-57. PubMed ID: 20406219
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.
    Abd Rahman AN; Tett SE; Staatz CE
    Clin Pharmacokinet; 2013 May; 52(5):303-31. PubMed ID: 23475567
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients.
    Li J; Liu Y; Huang J; Fu Q; Chen E; Liu L; Zhang R; Huang M; Wang C
    Am J Nephrol; 2013; 37(6):534-40. PubMed ID: 23689735
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Impact of intensive dosing of mycophenolate on pancreas allograft survival.
    Descourouez JL; Jorgenson MR; Menninga N; Leverson G; Odorico J; Redfield R
    Clin Transplant; 2018 Jul; 32(7):e13293. PubMed ID: 29791046
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.
    Pescovitz MD; Conti D; Dunn J; Gonwa T; Halloran P; Sollinger H; Tomlanovich S; Weinstein S; Inokuchi S; Kiberd B; Kittur D; Merion RM; Norman D; Shoker A; Wilburn R; Nicholls AJ; Arterburn S; Dumont E
    Clin Transplant; 2000 Jun; 14(3):179-88. PubMed ID: 10831074
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Mycophenolic Acid Trough Concentration and Dose Are Associated with Hematologic Abnormalities but Not Rejection in Kidney Transplant Recipients.
    Jung HY; Lee S; Jeon Y; Choi JY; Cho JH; Park SH; Kim YL; Kim HK; Huh S; Won DI; Kim CD
    J Korean Med Sci; 2020 Jun; 35(24):e185. PubMed ID: 32567256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.